The Legal Questions Behind a Pharmaceutical Manufacturing Move
A pharmaceutical company considering a new U.S. manufacturing site is not making a single decision. It is taking on a series of legal, regulatory and commercial questions at the same time.
Ipsen is reportedly evaluating whether to establish a U.S. manufacturing facility while continuing to invest in its U.K. operations. No final decision has been announced. Still, the issue illustrates what companies must examine when production strategy begins to shift. The Wall Street Journal, September 11, 2026
The first question is whether the company should build, acquire, expand an existing facility or use a contract manufacturer. Each path creates different obligations involving financing, real estate, construction, environmental review, licensing, employment and supply agreements.
The regulatory analysis is just as important. A facility may need to meet FDA requirements, address changes to manufacturing processes and maintain compliance during a transition. Moving production from one country to another can also affect inspections, documentation, release procedures and responsibilities between related companies and outside vendors.
Government incentives add another layer. Tax credits, grants and other programs may make a U.S. project more attractive, but they often come with eligibility rules, reporting requirements, employment commitments or limits on how funds may be used.
Trade policy also matters. Tariffs, country-of-origin rules and future changes in U.S. policy can affect the economics of a facility long after the initial investment decision has been made.
The legal work should begin before a company chooses a site. By then, the company should understand the regulatory pathway, the incentives it may qualify for, the contractual structure it needs and the risks of changing production later.
Manufacturing strategy is now part of the broader business strategy. Companies that treat it as only a real-estate or operations project may miss the legal and commercial consequences.
At Lanton, Lanton & Sosa Law PLLC, we help healthcare and life-sciences companies think through the legal, regulatory and government-affairs issues that arise when manufacturing, investment and market strategy begin to overlap. The earlier those questions are addressed, the more options a company usually has.
This article is for general educational purposes only and does not constitute legal advice. Specific manufacturing, regulatory, incentive and transactional questions should be reviewed with qualified counsel.